GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

TTI-101   Click here for help

GtoPdb Ligand ID: 12268

Synonyms: C188-9 [2] | TTI 101 | TTI101
Compound class: Synthetic organic
Comment: TTI-101 (Tvardi Therapeutics; formerly C188-9) is an orally bioavailable STAT3 transcription factor inhibitor. It blocks the tyrosine residue phosphorylation by Janus kinase (JAK) that mediates STAT3 activation, leading to downregulation of STAT3-mediated gene expression. This mechanism of action is considered as a valid approach for the treatment of inflammation, fibrosis, and a range of cancers [1,3]. The follow-on compound TTI-109, that is chemically distinct from TTI-101, has completed IND-enabling studies.

TTI-101 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 104.24
Molecular weight 471.11
XLogP 6.29
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COc1ccc(cc1)S(=O)(=O)Nc1cc(c(c2c1cccc2)O)c1c(O)ccc2c1cccc2
Isomeric SMILES COc1ccc(cc1)S(=O)(=O)Nc1cc(c(c2ccccc12)O)c1c(ccc2ccccc12)O
InChI InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3
InChI Key QDCJDYWGYVPBDO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
TTI-101 was advanced as a clinical lead for cancers and fibrotic diseases. In October 2025, Tvardi announced poor preliminary data from their phase 2 idiopathic pulmonary fibrosis (IPF) study, which suffered from high participant dropout rates (>55%, principally due to gastrointestinal adverse events) and placebo-like efficacy [5].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05440708 A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Phase 1/Phase 2 Interventional Tvardi Therapeutics, Incorporated
NCT05384119 Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor-Positive and Human Epithelial Receptor 2 (HER2)-Negative Breast Cancer Phase 1/Phase 2 Interventional Tvardi Therapeutics, Incorporated
NCT03195699 Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers Phase 1 Interventional Tvardi Therapeutics, Incorporated 4
NCT05671835 Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis Phase 2 Interventional Tvardi Therapeutics, Incorporated The REVERT-IPF study